Jessica’s practice focuses on defending clients facing government investigations and enforcement proceedings, as well as False Claims Act, Anti-Kickback and Stark litigation. This includes working with clients in both the healthcare and government contracting industries.  

Jessica also has significant complex commercial litigation experience representing corporations, officers and directors in class actions, securities litigation and contract disputes and conducting internal investigations on behalf of corporations. She has represented government contractors in disputes with federal and state government, and advised government contracting clients on compliance concerns.

Previously, Jessica served as an Assistant U.S. Attorney in the Affirmative Civil Enforcement Unit of the Civil Division of the U.S. Attorney’s Office for the Western District of Washington. While at the U.S. Attorney’s Office, Jessica led investigations of financial fraud against the federal government in the context of federal healthcare, defense and other programs. Jessica also defended the United States against civil claims in multiple contexts.

Education

  • University of Michigan Law School (J.D., cum laude, 2007)
    • Executive Editor, Michigan Journal of Law Reform
  • University of Washington (B.A., cum laude, 2003)

    Bar Admission

    • Washington
    • Alaska
    • Oregon

    Court Admissions

    • U.S. District Court, Western District of Washington
    • U.S. District Court, Eastern District of Washington
    • U.S. District Court, District of Alaska
    • U.S. Court of Appeals, Ninth Circuit
    • U.S. District Court, District of Oregon
    • U.S. Court of Appeals, Eighth Circuit

    Professional Affiliations

    • Institute for a Democratic Future, Board of Directors, 2016-Present, Fellow, 2013
    • Legal Voice, Board of Directors, 2015-2020
    • New Beginnings, Board of Directors, 2013-2019
    • Leadership Tomorrow, Fellow, 2013-2014
    • Seattle Human Rights Commission, Commissioner, Appeals Panel Chair, 2009-2013

    Recognition

    • Named “Litigation Star” by Benchmark Litigation, 2023-2026
    • Selected for inclusion in Best Lawyers in America® for:
      • Criminal Defense: White-Collar, 2024-2026
      • Litigation - Health Care, 2023-2026
      • Corporate Compliance Law, 2023-2025
      • Commercial Litigation, 2021-2026
    • Selected for Best Lawyers® “Lawyer of the Year” in Seattle, Washington, for Litigation – Health Care, 2026
    • Ranked in Chambers USA: America’s Leading Lawyers for Business, Washington:
      • Litigation: White-Collar Crime & Government, 2021-2025
      • Healthcare, 2023-2025
    • Selected for inclusion in Washington Super Lawyers, 2022
    • Selected for inclusion in Washington Super Lawyers, Rising Star, 2013-2014
    Publications
    2026 340B Program Update – 340B Rebate Model RFI Comments Due and Manufacturers Continue Restricting 340B Pricing
    Key Takeaways HRSA has extended the deadline for comments on its proposed 340B rebate model pilot program to April 20, 2026. Covered entities have a limited window to submit detailed feedback on how the model would affect operations and patient care. The proposed rebate model and new manufacturer data submission policies increase administrative burden and create risk of pricing denials and cash flow disruption. These changes could significantly expand compliance obligations and force providers into frequent disputes to recover 340B savings. Covered entities should submit detailed RFI comments and actively monitor 340B pricing access and denials. Providers should also begin tracking data, documenting losses and preparing for potential ADR filings and manufacturer engagement. The 340B program is experiencing rapid changes that could have a
    Read More
    The 340B Rebate Pilot: Voluntary for Manufacturers, Costly for 340B Covered Entities
    Key Takeaways HRSA’s 340B rebate pilot shifts financial and operational burden to covered entities, requiring upfront drug purchases with delayed, uncertain rebate recovery. Manufacturers can opt in, but covered entities cannot opt out, and face complex compliance obligations with limited recourse for withheld rebates. The pilot raises serious legal, regulatory and privacy concerns, including APA challenges and HIPAA risks tied to manufacturer-selected IT platforms. Comments are due by September 2, 2025, covered entities should evaluate legal options and consider targeted advocacy before the program launches January 1, 2026. HRSA published an announcement outlining a rebate pilot program (the rebate program) that would change how the 340B program has been operating since its inception. The rebate program would require covered entities, including hospitals and clinics, to front the
    Read More